Association between Pulse Pressure and Onset of Dementia in an Elderly Korean Population: A Cohort Study

Yongku Jung 1,†, Dong-Woo Choi 2,3,†, Sohee Park 4, Sung-In Jang 2,5 and Eun-Cheol Park 2,5,*

1 Department of Health Policy and Management, Graduate School of Public Health, Yonsei University, Seoul 03722, Korea; andrew.jung2008@gmail.com
2 Institute of Health Services Research, Yonsei University, Seoul 03722, Korea; CDW6027@yuhs.ac (D.-W.C.); jangsi@yuhs.ac (S.-I.J.)
3 Department of Public Health, Graduate School, Yonsei University, Seoul 03722, Korea
4 Department of Biostatistics, Yonsei University Graduate School of Public Health, Seoul 03722, Korea; soheepark@yuhs.ac
5 Department of Preventive Medicine, Yonsei University College of Medicine, Seoul 03722, Korea
* Correspondence: ecpark@yuhs.ac; Tel.: +82-2-2228-1862; Fax: +82-2-392-8133
† These authors contributed equally to this work.

Received: 7 January 2020; Accepted: 29 February 2020; Published: 4 March 2020

Abstract: Objective: There is paucity of studies on the association between pulse pressure and the development of dementia, although this association has already been established. This study aimed at investigating the association between pulse pressure and the onset of dementia. Methods: We used the South Korean National Health Insurance Service claims cohort data to select 149,663 patients without dementia aged ≥60 years. We calculated adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for dementia using Cox proportional hazard models according to a pulse pressure classification (<50, 50–59, 60–69, 70–79, 80–89, or 90+). Results: Compared to women with pulse pressure <50, those with pulse pressures of 50–59, 60–69, and 90+ had higher HRs for dementia (1.14, 1.22, and 1.03, respectively). These associations were particularly strong in those on Medicaid insurance and from rural regions. However, there were no statistically significant results among men. Conclusions: A higher pulse pressure was associated with an elevated risk of dementia in women aged >60 years, particularly those on Medicaid and from rural regions, possibly due to their inability to access hypertension and other medical treatment. The establishment of dementia indicators will help to guide future health policies for the prevention of dementia.

Keywords: pulse pressure; dementia; elderly; women; men

1. Introduction

Dementia is a major neuropsychiatric disorder, and is the fifth most common cause of death worldwide. Its prevalence has increased rapidly, leading to a high economic burden as a result of the growing social burden and costs related to the treatment to patients and their families [1]. Therefore, the early identification of factors that increase the risk of dementia is a critical task in terms of disease prevention, management, and policymaking [2]. For the early prevention of the onset of dementia, previous studies have identified several risk factors such as social, demographic, genetic, physical, and mental health factors [3–5].

Blood pressure is known to be an important indicator for predicting cardiovascular disease [6]. However, it is also recognized in the literature as a risk factor for dementia [7–9]. Elevated blood pressure likely to increase the risk for dementia by causing small-vessel disease and white-matter
lesions [7]. A previous study found that middle-aged men with high blood pressure or hypertension had a higher risk for late age dementia than others who were treated [8]. One study, on the other hand, said that low blood pressure may be a complication of the dementia process, particularly Alzheimer’s disease [9].

Previous studies on hypertension have mainly focused on diastolic blood pressure in cognitive function and dementia and in the investigation of the relationship between a high blood pressure and the onset of dementia [10–12]. The Whitehall II cohort study found that 130 mmHg or above systolic blood pressure at age 50 is related to increased risk for dementia in individuals free of cardiovascular disease [10]. In contrast, another study showed that low diastolic pressure may be associated with a higher risk of the onset of dementia in the elderly, i.e., over age 75, due to cerebral hypoperfusion [11]. A systolic hypertension trial in Europe also found new evidence that blood pressure lowering therapy initiated with long-acting dihydropyridine protects against dementia in older patients with systolic hypertension [12]. High blood pressure is also strongly associated with a decline in cognitive function among the elderly [13,14]. One meta-analysis study found that hypertension has adverse effects on cognition, can alter cerebral vasculature integrity, and is associated with the pathogenesis of dementia [13]. In addition, people with high blood pressure were found to be likely to experience a cognitive decline in a relatively short time period; the risk is highest in untreated hypertensive patients [14].

While systolic and diastolic blood pressure have been reported as indicators of the onset of dementia in some studies, there are no consistent results regarding the relationship between pulse pressure and dementia [15–18]. Previous studies found that higher pulse pressure was an indicator that pulse pressure is associated with increased risk of dementia [15–17]. One cohort study showed that higher pulse pressure due to artery stiffness and severe atherosclerosis may be related to increased risk of Alzheimer disease and dementia in old adults [15]. A trial on hypertension in the very elderly found that wider pulse pressure may be an indicator of an increased risk of dementia; notably, they focused on the association between diastolic blood pressure and dementia [16]. Moreover, one longitudinal study revealed that increasing the level of pulse pressure and pulse wave velocity, which are markers of arterial stiffness, was related to the onset of dementia [17]. On the other hand, Freitag’s team showed that there is no association between pulse pressure and incidence of dementia [18]. Given these inconsistencies, this study investigated the association between pulse pressure and the onset of dementia.

2. Methods

2.1. Data

This study used data from the South Korean National Health Insurance Service-Health Screening Cohort (NHIS-HEALS) database. This dataset included information gathered on approximately 515,000 patients between 2002 and 2013 and represents a random sample of 10% of the patient cohort stratified according to age, sex, health insurance type, income level, individual total medical costs, and clinical test results. The data also included a list of diagnoses according to the International Classification of Diseases version 10 (ICD-10), medical costs claimed, prescribed drugs, and medical history [19].

2.2. Study Population

We conducted a cohort study using a random sample of national health insurance service claims data. We excluded patients diagnosed with dementia between 2002 and 2003. We also excluded patients with missing values for the covariates. From the 2004 to 2010 claims data, we selected patients without preonset of dementia who were aged \( \geq 60 \). This resulted in a cohort of 149,663 patients.
2.3. Variables

The onset of dementia was defined by the ICD-10 codes G30, G31.1, G31.9, G31.8, F00, F03, and F05.1. Blood pressure was measured using an automated sphygmomanometer during routine health screenings conducted every two years as part of a national health screening program. Pulse pressure was defined as follows: systolic blood pressure–diastolic blood pressure. This information was obtained from the NHIS-HEALS database. Pulse pressures were classified into six groups, namely, ≤50, 50–59, 60–69, 70–79, 80–89, and ≥90.

Demographics and socioeconomic factors such as age, household income, and type of insurance were obtained from the NHIS-HEALS database. Patients were stratified into three groups based on their age as 60–69, 70–79, and ≥80 years. Patients were further stratified into quintiles based on their household income. Patients who paid 0% of health insurance premiums were classified as Medicaid, those who paid up to 20% were classified as low income, those who paid 21–80% were classified as middle income, and those who paid over 80% of the premium were classified as high income.

We used the Charlson comorbidity index (CCI) to measure comorbid conditions. The CCI assesses 19 diseases: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, diabetes without chronic complication, diabetes with chronic complication, hemiplegia or paraplegia, renal disease, any malignancy (including lymphoma and leukemia, except malignant neoplasm of the skin), moderate or severe liver disease, metastatic solid tumor, and AIDS/HIV. The CCI was calculated 1 year before patients were enrolled in the study [20]. The duration of treatment for hypertension (alpha- or beta-blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, diuretics, and calcium channel blockers), diabetes mellitus (sulfonylureas, metformin, thiazolidinedione, and alpha-glucosidase inhibitors), and dyslipidemia (any statins, fibrate, and omega 3 fatty acids) was determined using data on the duration of medications during the follow-up period. Hyperglycemia was defined as fasting blood glucose >110 mg/dL, measured in a clinical laboratory.

2.4. Statistical Analysis

We used descriptive statistics for the baseline characteristics of the study population. Differences between groups were determined using a chi-square test, t-test, and analysis of variance. Cumulative rates and incidence curves were constructed and compared using the Gray’s test for equality of cumulative incidence functions. Thereafter, we estimated the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for dementia by applying a Cox proportional hazard regression analysis according to sex. In this model, we adjusted for systolic and diastolic blood pressure; age; region; household income; type of insurance body mass index (BMI); disability status; charlson comorbidity index (CCI); duration of treatment for hypertension, diabetes mellitus, dyslipidemia, and hyperglycemia; hospital classification; and year. Lastly, we conducted a subgroup analysis according to the type of insurance and region. All statistical analyses were conducted with SAS version 9.4 (SAS institute, Inc., Cary, NC, USA) and R version 3.6 with package “cmprsk” (R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/). Statistical significance was set at \( p < 0.05 \).

3. Results

Table 1 shows baseline demographic characteristics of the study population. Among 149,663 patients, 73,272 were men and 76,391 were women. The rates of pulse pressure in the six groups (<50, 50–59, 60–69, 70–79, 80–89, and ≥90) were 1.6%, 1.8%, 1.9%, 1.9%, 2.2%, and 2.3%, respectively, in men and 2.5%, 2.7%, 3.1%, 3.1%, 3.5%, and 4.5%, respectively, in women with the onset of dementia. The total number of men and women with dementia was 1.8% and 2.7%, respectively. According to
age groups (60–69, 70–79, and ≥80 years), the percentages of participants were 70.0% \((n = 51,303)\), 27.7% \((n = 20,051)\), and 2.6% \((n = 1918)\) in men, 67.3% \((n = 51,449)\), 29.8% \((n = 22,764)\), 2.9% \((n = 2178)\) in women respectively.

Figure 1 shows the cumulative incidence function of dementia using the Gray’s test for pulse pressure. The cumulative incidence curve for the group of patients with pulse pressures of ≥90 was lower than that of other groups in both men \((p = 0.01)\) and women \((p < 0.0001)\).

![Figure 1. The cumulative incidence function of dementia using the Gray’s test for pulse pressure.](image)

Table 2 shows the adjusted HRs for dementia using Cox proportional hazard models for pulse pressure and covariates. Among women, the 50–59 (HR: 1.14, 95% CI: 1.04–1.25), 60–69 (HR: 1.22, 95% CI: 1.07–1.39), and ≥90 (HR: 1.03, 95% CI: 1.03–1.80) pulse pressure quartiles showed higher HRs for the incidence of dementia than the ≤50 quartile. However, there were no statistically significant differences for pulse pressure in men.

### Table 1. Baseline characteristics of the study population from 2004 to 2010.

| Variables              | Total | The Number and Incidence of Dementia | p–Value |
|------------------------|-------|--------------------------------------|---------|
|                        |       | Men | Women |       |
|                        |       | N  | %    | N  | %    |
| Pulse pressure         |       |    |      |    |      |
| <50                    | 57,608| 944 | 1.6  | 1428| 2.5  |
| 50–59                  | 49,610| 872 | 1.8  | 1344| 2.7  |
| 60–69                  | 27,046| 515 | 1.9  | 831 | 3.1  |
| ≥70–79                 | 10,595| 201 | 1.9  | 329 | 3.1  |
| ≥90                    | 3367  | 74  | 2.2  | 117 | 3.5  |
| Systolic blood pressure|       |    |      |    |      |
| <120                   | 50,755| 852 | 1.7  | 1403| 2.8  |
| 120–129                | 11,917| 177 | 1.5  | 270 | 2.3  |
| 130–139                | 39,039| 687 | 1.8  | 1007| 2.6  |
| ≥140                   | 47,952| 923 | 1.9  | 1433| 3.0  |
| Diastolic blood pressure|      |    |      |    |      |
| <60                    | 2046  | 31  | 1.5  | 62  | 3.0  |
| 61–80                  | 58,020| 1005| 1.7  | 1604| 2.8  |
| 81–90                  | 55,127| 955 | 1.7  | 1486| 2.7  |
| ≥90                    | 34,470| 648 | 1.9  | 961 | 2.8  |
| Age                    |       |    |      |    |      |
| 60–69                  | 102,752| 1269| 1.2  | 2001| 1.9  |
| 70–79                  | 42,815| 1212| 2.8  | 1873| 4.4  |
| ≥80                    | 4096  | 158 | 3.9  | 239 | 5.8  |
| Region                  | 0.0135  |
|-------------------------|---------|
| Capital area            | 46,295  |
| Metropolitan area       | 34,280  |
| Rural                   | 69,088  |

| Household income        | 0.0099  |
|-------------------------|---------|
| 1st quintile            | 29,273  |
| 2nd quintile            | 22,894  |
| 3rd quintile            | 22,747  |
| 4th quintile            | 30,458  |
| 5th quintile            | 44,291  |

| Types of insurance      | 0.0003  |
|-------------------------|---------|
| NHI, self–employed insured | 148,839 |
| Medical aid              | 824     |

| BMI                      | <0.0001 |
|--------------------------|---------|
| Underweight (<18.5)      | 70,488  |
| Normal (18.5–22.9)       | 44,447  |
| Overweight (23–24.9)     | 21,981  |
| Obesity (≥25)            | 12,747  |

| Disability               | 0.0361  |
|--------------------------|---------|
| Yes                      | 2419    |
| No                       | 147,244 |

| CCI                      | 0.0210  |
|--------------------------|---------|
| 0                        | 70,488  |
| 1                        | 44,447  |
| 2                        | 21,981  |
| 3+                       | 12,747  |

| Duration of treatment for hypertension | 0.0937 |
|----------------------------------------|--------|
| 0                                      | 45,413 |
| 1–365 days                             | 71,503 |
| 366–730 days                           | 21,096 |
| >730 days                              | 11,651 |

| Duration of treatment for diabetes mellitus | 1.0000 |
|---------------------------------------------|--------|
| 0                                          | 116,896|
| 1–365 days                                 | 20,851 |
| 366–730 days                               | 7303   |
| >730 days                                  | 4613   |

| Duration of treatment for dyslipidemia     | 0.2083 |
|--------------------------------------------|--------|
| 0                                          | 89,894 |
| 1–365 days                                 | 36,571 |
| 366–730 days                               | 14,350 |
| >730 days                                  | 8848   |

| Hyperglycemia                             | 0.1142 |
|-------------------------------------------|--------|
| No                                        | 116,463|
| Yes                                       | 33,200 |

| Hospital classification                   | 0.0298 |
|-------------------------------------------|--------|
| General hospital                          | 39,371 |
| Hospital                                  | 34,314 |
| Clinic                                    | 75,978 |

| Year                                      | 0.0540 |
|-------------------------------------------|--------|
| 2004                                      | 46,217 |
| 2005                                      | 50,882 |
| 2006                                      | 21,264 |
| 2007                                      | 13,830 |
| 2008                                      | 7331   |
| 2009                                      | 6808   |
| 2010                                      | 3331   |

| Total                                     | 4113   |

Note: BMI, Body mass index; CCI, Charlson comorbidity index; NHI, National health insurance.
Table 2. Adjusted hazard ratio for dementia using Cox proportional hazard models.

| Variables                        | Hazard Ratio of Dementia |         |         |         |
|----------------------------------|--------------------------|---------|---------|---------|
|                                  |                          | Men     | Women   |
|                                  | HRs 95% CIs | HRs 95% CIs |
| Pulse pressure                   |                          |         |         |         |
| <50                              | 1.00                     | 1.00    |
| 50–59                            | 1.00 (0.89–1.13)         | 1.14 (1.04–1.25) |
| 60–69                            | 0.99 (0.84–1.16)         | 1.22 (1.07–1.39) |
| 70–79                            | 0.91 (0.73–1.12)         | 1.14 (0.96–1.35) |
| 80–89                            | 1.03 (0.78–1.36)         | 1.15 (0.92–1.44) |
| ≥90                              | 1.03 (0.70–1.50)         | 1.37 (1.03–1.80) |
| Systolic blood pressure          |                          |         |         |         |
| <120                             | 1.00                     | 1.00    |
| 120–129                          | 0.91 (0.77–1.08)         | 0.85 (0.74–0.98) |
| 130–139                          | 1.00 (0.87–1.15)         | 0.83 (0.74–0.93) |
| >140                             | 1.02 (0.83–1.24)         | 0.83 (0.70–0.97) |
| Diastolic blood pressure         |                          |         |         |         |
| <60                              | 1.00                     | 1.00    |
| 61–80                            | 1.13 (0.79–1.62)         | 1.08 (0.84–1.40) |
| 81–90                            | 1.02 (0.71–1.48)         | 1.13 (0.86–1.47) |
| >90                              | 1.00 (0.68–1.48)         | 1.14 (0.86–1.51) |
| Age                              |                          |         |         |         |
| 60–69                            | 2.33 (2.14–2.53)         | 2.11 (1.98–2.25) |
| 70–79                            | 3.50 (2.95–4.16)         | 3.49 (3.03–4.01) |
| Region                           |                          |         |         |         |
| Capital area                     | 0.73 (0.67–0.81)         | 0.71 (0.65–0.77) |
| Metropolitan area                | 0.82 (0.75–0.91)         | 0.85 (0.78–0.92) |
| Rural                            | 1.00                     | 1.00    |
| Household income                 |                          |         |         |         |
| 1st quintile                     | 1.08 (0.96–1.21)         | 1.04 (0.95–1.13) |
| 2nd quintile                     | 1.09 (0.97–1.23)         | 0.97 (0.88–1.07) |
| 3rd quintile                     | 1.00 (0.88–1.13)         | 0.87 (0.78–0.96) |
| 4th quintile                     | 0.97 (0.86–1.08)         | 0.90 (0.82–0.99) |
| 5th quintile                     | 1.00                     | 1.00    |
| Types of insurance               |                          |         |         |         |
| NHI, self–employed insured       | 0.91 (0.56–1.47)         | 0.59 (0.45–0.77) |
| Medical aid                      | 1.00                     | 1.00    |
| BMI                              |                          |         |         |         |
| Underweight (<18.5)              | 0.85 (0.70–1.02)         | 1.11 (0.94–1.30) |
| Normal (18.5–22.9)               | 1.00                     | 1.00    |
| Overweight (23–24.9)             | 0.88 (0.80–0.97)         | 0.93 (0.85–1.00) |
| Obesity (≥25)                    | 0.83 (0.76–0.92)         | 0.87 (0.80–0.93) |
| Disability                       |                          |         |         |         |
| Yes                              | 1.41 (1.16–1.70)         | 1.23 (0.96–1.58) |
| No                               | 1.00                     | 1.00    |
| CCI                              |                          |         |         |         |
| 0                                | 1.00                     | 1.00    |
| 1                                | 1.12 (1.02–1.22)         | 1.16 (1.08–1.25) |
| 2                                | 1.10 (0.98–1.23)         | 1.28 (1.17–1.39) |
| 3+                               | 1.26 (1.11–1.43)         | 1.27 (1.13–1.41) |
| Duration of treatment for hypertension |                          |         |         |         |
| 0                                | 1.00                     | 1.00    |
| 1–365 days                       | 1.40 (1.26–1.55)         | 1.29 (1.18–1.41) |
| 366–730 days                     | 1.85 (1.59–2.16)         | 1.70 (1.48–1.95) |
| >730 days                        | 1.94 (1.57–2.41)         | 1.50 (1.21–1.85) |
Table 2. Cont.

| Duration of treatment for diabetes mellitus | HRs | 95% CIs     | HRs | 95% CIs     |
|------------------------------------------|-----|-------------|-----|-------------|
| 0                                        | 1.00| 1.00        |
| 1–365 days                               | 1.02| (0.89–1.16) | 1.24| (1.12–1.36) |
| 366–730 days                             | 1.21| (1.01–1.46) | 1.22| (1.05–1.41) |
| >730 days                                | 1.09| (0.86–1.37) | 1.21| (0.99–1.49) |

| Duration of treatment for dyslipidemia   | HRs | 95% CIs     | HRs | 95% CIs     |
|------------------------------------------|-----|-------------|-----|-------------|
| 0                                        | 1.00| 1.00        |
| 1–365 days                               | 1.14| (1.02–1.27) | 1.04| (0.96–1.13) |
| 366–730 days                             | 1.08| (0.91–1.28) | 1.10| (0.96–1.26) |
| >730 days                                | 1.22| (0.97–1.53) | 1.09| (0.87–1.36) |

| Hyperglycemia                            | HRs | 95% CIs     | HRs | 95% CIs     |
|------------------------------------------|-----|-------------|-----|-------------|
| No                                       | 1.00| 1.00        |
| Yes                                      | 0.97| (0.88–1.07) | 0.94| (0.87–1.02) |

| Hospital classification                   | HRs | 95% CIs     | HRs | 95% CIs     |
|------------------------------------------|-----|-------------|-----|-------------|
| General hospital                          | 0.98| (0.89–1.08) | 1.01| (0.93–1.09) |
| Hospital                                  | 1.05| (0.96–1.16) | 1.14| (1.05–1.22) |
| Clinic                                    | 1.00| 1.00        |

| Year                                      | HRs | 95% CIs     | HRs | 95% CIs     |
|------------------------------------------|-----|-------------|-----|-------------|
| 2004                                      | 1.00| 1.00        |
| 2005                                      | 1.15| (1.04–1.26) | 1.06| (0.98–1.15) |
| 2006                                      | 1.48| (1.30–1.69) | 1.22| (1.10–1.35) |
| 2007                                      | 1.60| (1.35–1.90) | 1.43| (1.26–1.62) |
| 2008                                      | 1.61| (1.22–2.11) | 1.79| (1.48–2.16) |
| 2009                                      | 1.62| (1.10–2.39) | 1.84| (1.43–2.38) |
| 2010                                      | 1.84| (0.76–4.48) | 2.06| (1.18–3.59) |

Note: BMI, Body mass index; CCI, Charlson comorbidity index; NHI, National health insurance.

Table 3 shows the adjusted HRs for the subgroup analysis. For women in the Medicaid group, the 50–59 (HR: 5.71, 95% CI: 2.02–16.12), 60–69 (HR: 9.16, 95% CI: 2.31–36.36), 70–79 (HR: 17.53, 95% CI: 3.23–95.12), 80–89 (HR: 19.91, 95% CI: 3.59–110.56), and ≥90 (HR: 86.80, 95% CI: 11.76–1.640.69) pulse pressure quartiles were associated with higher HRs for the incidence of dementia than the ≤50 quartile. However, there were no statistically significant results for men. For women who lived in the capital area, the 50–59 and 60–69 pulse pressure quartile groups had higher HRs than the ≤50 group. For women who lived in rural areas, only the ≥90 pulse pressure group had a higher HR than the ≤50 group.

Table 3. Adjusted hazard ratio for incidence of dementia according to subgroups using Cox proportional hazard models*.

| Subgroups          | Pulse Pressure | Hazard Ratio of Dementia |
|--------------------|----------------|-------------------------|
|                    |                | Men                     | Women                   |
|                    |                | HRs | 95% CIs | HRs | 95% CIs |
| Types of insurance |                |                |                       |
| NHI, self-employed insured | <50 | 1.00 | 1.00 | 1.00 | 1.00 |
|                      | 50–59          | 1.00 | (0.89–1.13) | 1.12 | (1.02–1.24) |
|                      | 60–69          | 0.98 | (0.84–1.16) | 1.20 | (1.05–1.37) |
|                      | 70–79          | 0.90 | (0.73–1.12) | 1.11 | (0.93–1.31) |
|                      | 80–89          | 1.00 | (0.76–1.33) | 1.11 | (0.88–1.39) |
|                      | ≥90            | 1.03 | (0.71–1.51) | 1.28 | (0.97–1.71) |
| Medical aid         |                |                |                       |
| <50                 | 1.00          | 1.00          |
| 50–59               | 0.81          | (0.12–5.55) | 5.71 | (2.02–16.12) |
| 60–69               | 1.07          | (0.06–19.99) | 9.16 | (2.31–36.36) |
| 70–79               | 4.12          | (0.11–151.70) | 17.53 | (3.23–95.12) |
| 80–89               | 7.88          | (0.31–199.00) | 19.91 | (3.59–110.56) |
| ≥90                 | 86.80         | 86.80         |

Note: NHI, National health insurance; Analysis was adjusted for the following covariates: systolic blood pressure, diastolic blood pressure, age, region, household income, BMI, CCI, duration of treatment for hypertension, diabetes mellitus, dyslipidemia, hyperglycemia, hospital classification, and year.
4. Discussion

This study examined the association between pulse pressure and the onset of dementia among men and women. After controlling for several covariates, elderly women with a high pulse pressure were shown to have a significantly higher rate of onset of dementia than those with a low pulse pressure. Moreover, these associations were strong among women in the Medicaid group who lived in rural areas.

The results from this study showed that high pulse pressure levels were associated with the risk of developing dementia. These results are similar to those from previous studies that reported the association between an elevated pulse pressure and decreased cognitive function in community members aged 55–64 years using data from the Framingham Offspring Cohort Study conducted to identify risk factors for cardiovascular disease during the 1998–2009 period [21]. In addition, previous studies have demonstrated an association between an increased pulse pressure and pulse rate and decreased cognitive function [16,22]. The association between high pulse pressure levels and an increased risk of developing dementia may be explained by the traditional belief that dementia is a cerebral neurodegenerative disease that occurs as a result of the accumulation of β-amyloid, as well as the method of reporting and interpreting it as a result of cerebral white matter changes due to vascular diseases [23]. On the other hand, more recent studies offer evidence for the role of the disconnection hypothesis of Alzheimer’s disease due to white matter lesions of the frontal-prefrontal cortical-subcortical circuits accounting for cognition and mood-affect [24–28]. These findings have been supported using transcranial magnetic stimulation and transcranial Doppler sonography.

Another possibility is that pulse pressure has a high positive correlation with plasma B-type natriuretic peptide (BNP), and high BNP levels have a high correlation with microvascular damage. Therefore, damage and disease in the microvessels of the cerebrum cause the denaturation of blood vessels. These negative changes in the blood vessels destroy the function of the blood–brain barrier, thereby increasing the accumulation of β-amyloid due to increased permeability and protein run-off in the cerebral cortex [29–33].

In contrast, atherosclerosis, a vascular disease, of the blood vessels leads to a rise in the blood pressure. Vascular rigidity and atherosclerosis increase the risk of dementia, indicating that vascular diseases impose a similar risk as cardiovascular disease [34–36]. It has also been reported that blood vessel-rigidity can cause microvascular disorders and diseases in the brain [37]. Rigidity reduces the absorption of waves in the arteries, leading to an increased pressure in blood flow to the capillaries of the brain. These disorders of the cerebral blood vessels can increase the white matter in the brain, which is common in patients with dementia [37]. Therefore, pulse pressure and the range of white matter lesions in the brain and their severity are highly relevant. White matter abnormalities are also highly related to cognitive impairment [38–42]. It can be inferred that high pulse pressure levels are associated with increased brain white matter lesions and the occurrence of dementia through microvessel disorders in the cerebrum [38–42]. Therefore, those diseases are likely to be synergistic effects to developing dementia [43]. Moreover, one study found the possibility that pulse pressure may be also related to increased cerebrospinal fluid and phosphorylated-tau in normal elderly [44]. It is possible that pulsatile hemodynamics may be associated with amyloidosis and tau-related neurodegeneration [44].

In this study, the association between a high pulse pressure and the high risk of developing dementia was evident only in women. This observation was similar to that of previous studies conducted in elderly [16,45]. One study found that lower pulse pressure was 1.4 times more common among women than men [45]. This study proposed that the association between pulse pressure and dementia is due to artery stiffness and severe atherosclerosis, and poor cerebral perfusion [45]. Another study also found that women were 1.5 times more likely than men to have a probability of Alzheimer’s disease and severity of cognitive impairment [16]. Although we could not find the underlying mechanisms for the difference between sexes, we guess that it is possible that women often receive less education, and are subject to the stronger effect of Apolipoprotein E, and bilateral oophorectomy compared to men [46]. In contrast, depressive symptoms may affect the increasing
risk of dementia in elderly women. Many studies have found that women are more likely to be with depressive symptoms than men [47–50]. This may be due to differences in genetic influence and the social role of women, e.g., as caregivers, living alone, and social support [47–50]. Depressive symptoms could be related to dementia. A previous study mentioned that vascular depression may also be related to white matter lesions due to vascular damage to frontal subcortical circuits [38]. Therefore, these factors may have led to the high incidence of dementia in elderly women. However, we could not take into account the proportion of depressive symptoms among both men and women at baseline, which may have affected the results. Despite these studies, medical or biological explanations for the elevated risk of dementia in women remain controversial due to a paucity of evidence; therefore, further research is needed.

Our study had several limitations. First, because the follow-up period from the medical examination to the onset of dementia took place over a 10-year-period, it is possible that we under- or over-estimated the link between the measurement of blood pressure and fasting blood glucose depending on the time of the examination or the current health condition of the patient. In addition, we could not include patients who did not undergo blood pressure testing or a health check-up every 2 years. However, blood pressure was measured at a clinical laboratory; therefore, the measurements were reliable. Second, although we used the ICD-10 codes for the diagnosis of dementia, this might have been overestimated due to up-coding errors or misclassification biases associated with the claims data. Therefore, the results should be interpreted with caution. Finally, there is an added potential for the overestimation or undervaluation of statistical results due to unadjusted confounding factors.

5. Conclusions

Although our findings need further confirmation, we believe that there is an association between pulse pressure and the incidence of dementia. A higher pulse blood pressure is associated with an elevated risk of dementia in individuals aged >60 years, but only in women. Furthermore, the results from the subgroup analysis revealed that elderly women with Medicaid living in rural areas should be targeted so that interventions aimed at preventing dementia can be implemented among this population.

**Author Contributions:** Conceptualization, E.-C.P.; Methodology, S.P.; Project administration, E.-C.P.; Writing—original draft, Y.J. and D.-W.C.; Writing—review & editing, S.-I.J. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Park, H.-Y.; Park, J.-W.; Song, H.J.; Sohn, H.S.; Kwon, J.-W. The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea. *PLoS ONE* 2017, 12, e0169463. [CrossRef] [PubMed]
2. Wu, Y.-T.; Fratiglioni, L.; Matthews, F.E.; Lobo, A.; Breteler, M.M.B.; Skoog, I.; Brayne, C. Dementia in western Europe: Epidemiological evidence and implications for policy making. *Lancet Neurol.* 2016, 15, 116–124. [CrossRef]
3. Pendlebury, S.T.; Rothwell, P.M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: A systematic review and meta-analysis. *Lancet Neurol.* 2009, 8, 1006–1018. [CrossRef]
4. Fratiglioni, L.; Wang, H.-X.; Ericsson, K.; Maytan, M.; Winblad, B. Influence of social network on occurrence of dementia: A community-based longitudinal study. *Lancet* 2000, 355, 1315–1319. [CrossRef]
5. Fleminger, S.; Oliver, D.L.; Lovestone, S.; Rabe-Hesketh, S.; Giora, A. Head injury as a risk factor for Alzheimer’s disease: The evidence 10 years on; a partial replication. *J. Neurol. Neurosurg. Psychiatry* 2003, 74, 857. [CrossRef] [PubMed]
6. Collaboration, A.P.C.S. Blood pressure and cardiovascular disease in the Asia Pacific region. *J. Hypertens.* 2003, 21, 707–716.
7. Skoog, I.; Nilsson, L.; Persson, G.; Lernfelt, B.; Landahl, S.; Palmertz, B.; Andreasson, L.; Odén, A.; Svanborg, A. 15-year longitudinal study of blood pressure and dementia. *Lancet* 1996, 347, 1141–1145. [CrossRef]

8. Launer, L.J.; Ross, G.W.; Petrovitch, H.; Masaki, K.; Foley, D.; White, L.R.; Havlik, R.J. Midlife blood pressure and dementia: The Honolulu–Asia aging study. *Neuropsychobiology* 2000, 21, 49–55. [CrossRef]

9. Guo, Z.; Viitanen, M.; Fratiglioni, L.; Winblad, B. Low blood pressure and dementia in elderly people: The Kungsholmen project. *BMJ* 1996, 312, 805. [CrossRef]

10. Abell, J.G.; Kivimäki, M.; Dugravot, A.; Tabak, A.G.; Fayosse, A.; Shipley, M.; Sabia, S.; Singh-Manoux, A. Association between systolic blood pressure and dementia in the Whitehall II cohort study: Role of age, duration, and threshold used to define hypertension. *Eur. Heart J.* 2018, 39, 3119–3125. [CrossRef]

11. Verghese, J.; Lipton, R.B.; Hall, C.B.; Kuslansky, G.; Katz, M.J. Low blood pressure and the risk of dementia in very old individuals. *Neurology* 2003, 61, 1667. [CrossRef] [PubMed]

12. Birkenhäger, W.H.; Forette, F.; Seux, M.-L.; Wang, J.-G.; Staessen, J.A. Blood Pressure, Cognitive Functions, and Prevention of Dementia in Older Patients with Hypertension. *JAMA Intern. Med.* 2001, 161, 152–156. [CrossRef] [PubMed]

13. Peters, R.; Beckett, N.; Fagard, R.; Thijs, L.; Wang, J.-G.; Forette, F.; Pereira, L.; Fletcher, A.; Bulpitt, C. Increased pulse pressure linked to dementia: Further results from the Hypertension in the Very Elderly Trial–HYVET. *J. Hypertens.* 2013, 31, 1868–1875. [CrossRef]

14. Waldstein, S.R.; Rice, S.C.; Thayer, J.F.; Najjar, S.S.; Scuteri, A.; Zonderman, A.B. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. *Hypertension* 2008, 51, 99–104. [CrossRef]

15. Qiu, C.; Winblad, B.; Viitanen, M.; Fratiglioni, L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. *Stroke* 2003, 34, 594–599. [CrossRef]

16. Peters, R.; Beckett, N.; Fagard, R.; Thijs, L.; Wang, J.-G.; Forette, F.; Pereira, L.; Fletcher, A.; Bulpitt, C. Increased pulse pressure linked to dementia: Further results from the Hypertension in the Very Elderly Trial–HYVET. *J. Hypertens.* 2013, 31, 1868–1875. [CrossRef]

17. Waldstein, S.R.; Rice, S.C.; Thayer, J.F.; Najjar, S.S.; Scuteri, A.; Zonderman, A.B. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. *Hypertension* 2008, 51, 99–104. [CrossRef]

18. Freitag, M.H.; Peila, R.; Masaki, K.; Petrovitch, H.; Ross, G.W.; White, L.R.; Launer, L.J. Midlife pulse pressure and incidence of dementia: The Honolulu–Asia Aging Study. *Stroke* 2006, 37, 33–37. [CrossRef]

19. Seong, S.C.; Kim, Y.-Y.; Park, S.K.; Khang, Y.H.; Kim, H.C.; Park, J.H.; Kang, H.-J.; Do, C.-H.; Song, J.-S.; Lee, E.-J.; et al. Cohort profile: The National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. *BMJ Open* 2017, 7, e016640. [CrossRef]

20. Hwang, I.C.; Chang, J.; Park, S.M. A Nationwide Population-Based Cohort Study of Dementia Risk Among Acid Suppressant Users. *Am. J. Geriatr. Psychiatry* 2018, 26, 1175–1183. [CrossRef]

21. Nation, D.A.; Preis, S.R.; Beiser, A.; Bangen, K.J.; Delano-Wood, L.; Lamar, M.; Libon, D.J.; DeCarli, C.; Seshadri, S.; Wolf, P.A.; et al. Pulse Pressure Is Associated With Early Brain Atrophy and Cognitive Decline: Modifying Effects of APOE-ε4. *Alzheimer Dis. Assoc. Disord.* 2016, 30, 210–215. [CrossRef] [PubMed]

22. Waldstein Shari, R.; Rice, S.C.; Thayer Julian, F.; Najjar Samer, S.; Scuteri, A.; Zonderman Alan, B. Pulse Pressure and Pulse Wave Velocity Are Related to Cognitive Decline in the Baltimore Longitudinal Study of Aging. *Hypertension* 2008, 51, 99–104. [CrossRef] [PubMed]

23. Iadecola, C.; Davison, R.L. Hypertension and Cerebrovascular Dysfunction. *Cell Metab.* 2008, 7, 476–484. [CrossRef] [PubMed]

24. Van Der Flier, W.M.; Skoog, I.; Schneider, J.A.; Pantoni, L.; Mok, V.; Chen, C.L.; Scheltens, P. Vascular cognitive impairment. *Nat. Rev. Dis. Primers* 2018, 4, 1–16. [CrossRef]

25. Lanza, G.; Bella, R.; Giuffrida, S.; Cantone, M.; Pennisi, G.; Spampinato, C.; Giordano, D.; Malaguarnera, G.; Raggi, A.; Pennisi, M. Preserved transcallosal inhibition to transcranial magnetic stimulation in nondemented elderly patients with leukoaraiosis. *BioMed Res. Int.* 2013, 2013, 351680. [CrossRef]

26. Puglisi, V.; Bramanti, A.; Lanza, G.; Vinciguerra, L.; Pennisi, M.; Bonanno, L.; Pennisi, G.; Bella, R. Impaired cerebral haemodynamics in vascular depression: Insights from transcranial doppler ultrasonography. *Front. Psychiatry* 2018, 9, 316. [CrossRef]

27. Vinciguerra, L.; Lanza, G.; Puglisi, V.; Pennisi, M.; Cantone, M.; Bramanti, A.; Pennisi, G.; Bella, R. Transcranial Doppler ultrasound in vascular cognitive impairment-no dementia. *PLoS ONE* 2019, 14, e0216162. [CrossRef]
28. Concerto, C.; Lanza, G.; Cantone, M.; Ferri, R.; Pennisi, G.; Bella, R.; Aguglia, E. Repetitive transcranial magnetic stimulation in patients with drug-resistant major depression: A six-month clinical follow-up study. *Int. J. Psychiatry Clin. Pract.* 2015, 19, 252–258. [CrossRef]

29. Hashimoto, J.; Ito, S. Central pulse pressure links microalbuminuria with plasma B-type natriuretic peptide elevation: Causal implication for cardio-renal syndrome in hypertension. *J. Hypertens.* 2014, 32, 1665–1671. [CrossRef]

30. Mutlu, U.; Ikram, M.A.; Hofman, A.; de Jong, P.T.; Klaver, C.C.; Ikram, M.K. N-Terminal Pro-B-Type Natriuretic Peptide Is Related to Retinal Microvascular Damage: The Rotterdam Study. *Arterioscler. Thromb. Vasc. Biol.* 2016, 36, 1698–1702. [CrossRef]

31. Liu, Y.; Braidy, N.; Poljak, A.; Chan, D.K.; Sachdev, P. Cerebral small vessel disease and the risk of Alzheimer’s disease: A systematic review. *Ageing Res. Rev.* 2018, 47, 41–48. [CrossRef] [PubMed]

32. Van Popele, N.M.; Grobbee, D.E.; de Jong, P.T.; Klaver, C.C.; Ikram, M.K. N-Terminal Pro-B-Type Natriuretic Peptide Is Related to Retinal Microvascular Damage: The Rotterdam Study. *Arterioscler. Thromb. Vasc. Biol.* 2016, 36, 1698–1702. [CrossRef]

33. Bella, R.; Pennisi, G.; Cantone, M.; Palermo, F.; Pennisi, M.; Lanza, G.; Zappia, M.; Paolucci, S. Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease. *Gerontology* 2010, 56, 298–302. [CrossRef] [PubMed]

34. Prins, N.D.; van Dijk, E.J.; den Heijer, T.; Vermeer, S.E.; Koudstaal, P.J.; Oudkerk, M.; Hofman, A.; Breteler, M.M. Cerebral white matter lesions and the risk of dementia. *Arch. Neurol.* 2004, 61, 1531–1534. [CrossRef]

35. Kim, C.K.; Lee, S.-H.; Kim, B.J.; Ryu, W.-S.; Yoon, B.-W. Age-independent association of pulse pressure with cerebral white matter lesions in asymptomatic elderly individuals. *J. Hypertens.* 2011, 29, 325–329. [CrossRef]

36. Zhou, X. Blood Pressure, Pulse Pressure, and Antihypertensive Treatment: Association with Cognitive Decline and Dementia in Elderly Mexican-Americans. Ph.D. Thesis, University of Michigan, Ann Arbor, MI, USA, 2010. Available online: http://hdl.handle.net/2027.42/75868 (accessed on 5 March 2020).

37. O’Rourke, M.F.; Safar, M.E. Relationship between aortic stiffening and microvascular disease in brain and kidney: Cause and logic of therapy. *Hypertension 2005*, 46, 200–204. [CrossRef] [PubMed]

38. Bella, R.; Pennisi, G.; Cantone, M.; Palermo, F.; Pennisi, M.; Lanza, G.; Zappia, M.; Paolucci, S. Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease. *Gerontology* 2010, 56, 298–302. [CrossRef] [PubMed]

39. Prins, N.D.; van Dijk, E.J.; den Heijer, T.; Vermeer, S.E.; Koudstaal, P.J.; Oudkerk, M.; Hofman, A.; Breteler, M.M. Cerebral white matter lesions and the risk of dementia. *Arch. Neurol.* 2004, 61, 1531–1534. [CrossRef]

40. Kim, C.K.; Lee, S.-H.; Kim, B.J.; Ryu, W.-S.; Yoon, B.-W. Age-independent association of pulse pressure with cerebral white matter lesions in asymptomatic elderly individuals. *J. Hypertens.* 2011, 29, 325–329. [CrossRef]

41. Liu, Y.; Braidy, N.; Poljak, A.; Chan, D.K.; Sachdev, P. Cerebral small vessel disease and the risk of Alzheimer’s disease: A systematic review. *Ageing Res. Rev.* 2018, 47, 41–48. [CrossRef] [PubMed]

42. Breteler, M.M.B.; Van Swieten, J.C.; Bots, M.L.; Grobbee, D.E.; Claus, J.J.; Van Den Hout, J.H.W.; Van Harskamp, F.; Tanghe, H.L.J.; De Jong, P.T.V.M.; Van Gijn, J.; et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study. *Rotterdam Study 1994*, 44, 1246. [CrossRef] [PubMed]

43. Bordet, R.; Ihl, R.; Korczyn, A.D.; Lanza, G.; Janss, J.; Hoerr, R.; Guekht, A. Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: A consensus report. *BMC Med.* 2017, 15, 107. [CrossRef] [PubMed]

44. Nation, D.A.; Edland, S.D.; Bondi, M.W.; Salmon, D.P.; Delano-Wood, L.; Peskind, E.R.; Quinn, J.F.; Galasko, D.R. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. *Neurology 2013*, 81, 204. [CrossRef] [PubMed]

45. Ronquillo, J.G.; Baer, M.R.; Lester, W.T. Sex-specific patterns and differences in dementia and Alzheimer’s disease using informatics approaches. *J. Women Aging* 2016, 28, 403–411. [CrossRef] [PubMed]

46. Rocca, W.A.; Mielke, M.M.; Vemuri, P.; Miller, VM. Sex and gender differences in the causes of dementia: A narrative review. *Maturitas* 2014, 79, 196–201. [CrossRef] [PubMed]

47. Yaffie, K.; Blackwell, T.; Gore, R.; Sands, L.; Reus, V.; Browner, W.S. Depressive Symptoms and Cognitive Decline in Nondemented Elderly Women: A Prospective Study. *Arch. Gen. Psychiatry 1999*, 56, 425–430. [CrossRef]
48. Park, J.; Lee, S.; Lee, T.; Lee, D.; Jhoo, J.; Youn, J.; Choo, I.; Choi, E.; Jeong, J.; Choe, J. Depression in vascular dementia is quantitatively and qualitatively different from depression in Alzheimer’s disease. *Dement. Geriatr. Cogn. Disord.* 2007, 23, 67–73. [CrossRef]

49. Stoppe, G.; Sandholzer, H.; Huppertz, C.; Duwe, H.; Staedt, J. Gender differences in the recognition of depression in old age. *Maturitas* 1999, 32, 205–212. [CrossRef]

50. D’Epinay, C.J.L. Depressed elderly women in Switzerland: An example of testing and of generating theories. *Gerontologist* 1985, 25, 597–604. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).